Intellia Therapeutics Inc (NASDAQ: NTLA) kicked off on Monday, up 2.35% from the previous trading day, before settling in for the closing price of $8.09. Over the past 52 weeks, NTLA has traded in a range of $5.90-$28.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 6.07%. While this was happening, its average annual earnings per share was recorded 20.55%. With a float of $97.48 million, this company’s outstanding shares have now reached $103.54 million.
Considering the fact that the conglomerate employs 403 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 88.67%, operating margin of -1187.36%, and the pretax margin is -1154.1%.
Intellia Therapeutics Inc (NTLA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 5.90%, while institutional ownership is 92.21%. The most recent insider transaction that took place on Apr 29 ’25, was worth 2,252. In this transaction Director of this company sold 265 shares at a rate of $8.50, taking the stock ownership to the 19,203 shares. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, Chief Technical Officer sold 679 for $8.99, making the entire transaction worth $6,104. This insider now owns 95,369 shares in total.
Intellia Therapeutics Inc (NTLA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.48% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Take a look at Intellia Therapeutics Inc’s (NTLA) current performance indicators. Last quarter, stock had a quick ratio of 4.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.23, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -3.85 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Compared to the last year’s volume of 3.8 million, its volume of 5.63 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 39.10%. Additionally, its Average True Range was 0.74.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 34.29%, which indicates a significant decrease from 49.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 130.92% in the past 14 days, which was higher than the 94.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.93, while its 200-day Moving Average is $12.97.
